Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity - Wikidata - awgldk - TriplyDB

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

http://www.wikidata.org/entity/Q27487377

about

The dengue vaccine pipeline: Implications for the future of dengue control Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review Understanding the dengue viruses and progress towards their control Serotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus Family Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers Dengue virus-induced hemorrhage in a nonhuman primate model The chimeric Japanese encephalitis/Dengue 2 virus protects mice from challenge by both dengue virus and JEV virulent virus Dengue research opportunities in the Americas Issues related to recent dengue vaccine development.Current progress in dengue vaccines Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.Report of an NIAID workshop on dengue animal models.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Dengue vaccines: recent developments, ongoing challenges and current candidates.Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development.Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies Targeted mutagenesis as a rational approach to dengue virus vaccine development.Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity.Immunologic hypo- or non-responder in natural dengue virus infection

P2860

Q26314683-3316AEFD-E46A-4C2D-9101-BCBB9972C66C Q26700078-042B070D-5C37-4640-824D-6BF0DE92BBF3 Q27011587-70A45B06-A4A4-4225-B563-E5787E90FCDC Q27490960-5BB8C501-6F90-4697-AF33-8EB49211B406 Q27490989-B7FF6BE3-0A09-4940-802A-3F13B5A00F05 Q27491021-51C61225-B322-4661-9B5F-C7C48B956917 Q28578809-C3FBF175-30BA-45B2-B159-4A4C303D75E2 Q28656204-D8CD9D4E-D455-443C-B675-BB0B415E5D63 Q30395396-D6ED8119-C2E5-4633-8F7F-DF057C89AC7C Q33408300-E0A9E242-B7F4-4718-BB38-A91E46C35D6E Q33961878-F1F6AE76-1A5C-4295-99D7-7F714B005155 Q34058747-472F3748-4941-43DE-A927-89FDACECF038 Q34202440-F9359F79-8552-4680-AF44-F417B9FB2E3C Q34367194-B5378625-2907-4C78-98A1-43EDB3885C24 Q34763787-DF98597F-50D2-4F62-BC39-3443882B4D4B Q35195545-BA5C2945-7068-4059-911F-698CF616C3AD Q35206695-2C20B49C-A75C-44F5-BC12-478EFCC16D5D Q35758626-7E5AE48D-08BE-43C4-A143-3A01985D098A Q36118259-1B1531C0-DBFC-4218-A150-8AB1E3B8B954 Q36181531-461BAC0A-CE00-407A-8AB9-069360497655 Q36607295-808A01BD-0166-4655-9215-45C5BC715E83 Q36756643-5F309D39-8FD0-4269-A347-50F74BDC4BD5 Q36922684-63E379BE-A8CE-4E0E-B5CD-BEE5562FB387

P2860

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity

http://www.wikidata.org/entity/Q27487377

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@ast

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@en

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@nl

type

label

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@ast

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@en

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@nl

prefLabel

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@ast

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@en

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@nl

P1433

Q27487377-9841831E-A244-4EFB-B02C-3BB902AA0258

P1476

Q27487377-B87AA60F-E200-4DFE-9BC5-BE4F61C26212

P2093

Q27487377-57EDB78C-B007-49BF-BAD7-602F686F46CB

Q27487377-722FBE5B-77FA-46D5-B769-2A29F02B8777

Q27487377-A806AABD-6875-4F30-849C-8BE500C06D5E

Q27487377-AA322147-E91F-4C5F-8417-B3985E46B247

Q27487377-B5D3B9D8-60DD-4741-9D73-D1570463AF42

Q27487377-D99279B7-5806-4A68-92FA-4FB4E0750263

Q27487377-EBE180D1-AB39-40F1-AABA-E17B70D4264E

Q27487377-F6FF037D-0ECA-41F6-969C-6D73F1FD7222

P2860

Q27487377-0044B9BE-7895-4563-BC54-69DEAC8B88DE

Q27487377-1C74EBB3-52EF-4AE1-B2F1-07C9F804F876

Q27487377-2130D9F6-BFA4-40AB-8F7A-AABDDF15CCB4

Q27487377-270ABCFD-4A3C-4721-8FC8-AD3C72E5649B

Q27487377-278A1537-2823-41CA-B82C-6BE0AC6D79E4

Q27487377-31D8B643-B06A-426D-98FF-DFA81CCA5F7F

Q27487377-5B5B3C90-8F6F-4CC3-BF0C-C9525A8D00A9

Q27487377-5B803603-43C6-45D0-B563-C2FDB93BC70D

Q27487377-64ABD88C-B225-4561-AEE7-A1298F67E8E9

Q27487377-6BEE829A-264C-4C06-A39E-08EF2F73D626

P304

Q27487377-7003482A-6090-45AF-8537-82E0EEBEFBDC

P31

Q27487377-955664C1-DD08-4092-9808-8D3FC9762A1B

P3181

Q27487377-7CBD638F-C204-424D-8137-E36E9CE6A7A8

P407

Q27487377-2B500301-CBC5-4F71-9749-D82B5C8EB714

P433

Q27487377-A739AA6F-F9B1-4634-AE86-D5EA1319D161

P478

Q27487377-9DBEC870-59BA-4ECE-A145-B32ECCD25EC8

P50

Q27487377-007729A2-CAB6-457D-B426-FA8CB2202B25

Q27487377-BEC5E356-D9D5-4A9B-8762-E270E23BABDF

P577

Q27487377-6621BB0E-6215-4320-A71B-606D02888ED0

P698

Q27487377-C3D00864-F296-4638-A147-68410EF1246F

P921

Q27487377-38C360F4-57E8-4C4B-B034-DB1ECCB6B30B

Q27487377-85E73178-6D13-4091-8E13-BB4943BE76C9

Q27487377-CF710020-1229-4523-AF80-A747155E0AD6

P932

Q27487377-A1301EFF-51F7-471B-AAC5-78A50C16030A

P3181

P1433

American Journal of Tropical Medicine and Hygiene

P1476

Phase I clinical evaluation of ...... d for decreased hepatotoxicity

@en

P2093

Alexander C Schmidt

http://www.w3.org/2001/XMLSchema#string

Bhavin Thumar

http://www.w3.org/2001/XMLSchema#string

Brian R Murphy

http://www.w3.org/2001/XMLSchema#string

Dennis J Pierro

http://www.w3.org/2001/XMLSchema#string

Jennifer A Marron

http://www.w3.org/2001/XMLSchema#string

Joseph E Blaney

http://www.w3.org/2001/XMLSchema#string

Julie H McArthur

http://www.w3.org/2001/XMLSchema#string

Kimberli A Wanionek

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring the burden of neglected tropical diseases: the global burden of disease framework

Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes.

A prospective study of dengue infections in Bangkok

Research on dengue during World War II

Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever

Prospects for a dengue virus vaccine

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

Clinical observations of virologically confirmed dengue fever in the 1987 outbreak in southern Taiwan.

Development of a live attenuated dengue virus vaccine using reverse genetics.

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

P304

678-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4131937

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Stephen S Whitehead

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18981503

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

2590927

http://www.w3.org/2001/XMLSchema#string